RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Carisma Therapeutics Stock

Carisma Therapeutics Equity 2024

Carisma Therapeutics Equity

26.53 M USD

Ticker

CARM

ISIN

US14216R1014

WKN

A3DZG2

In 2024, Carisma Therapeutics's equity was 26.53 M USD, a -83.23% increase from the 158.2 M USD equity in the previous year.

Carisma Therapeutics Aktienanalyse

What does Carisma Therapeutics do?

Carisma Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Carisma Therapeutics's Equity

Carisma Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Carisma Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Carisma Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Carisma Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Carisma Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Carisma Therapeutics stock

What is the equity of Carisma Therapeutics this year?

Carisma Therapeutics has equity of 26.53 M USD this year.

What was the equity of Carisma Therapeutics compared to the previous year?

The equity of Carisma Therapeutics has increased/decreased by -83.23% decreased compared to the previous year.

What impact does a high equity have on investors of Carisma Therapeutics?

A high equity is advantageous for investors of Carisma Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Carisma Therapeutics?

A low equity can be a risk for investors of Carisma Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Carisma Therapeutics affect the company?

An increase in equity of Carisma Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Carisma Therapeutics affect the company?

A reduction in equity of Carisma Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Carisma Therapeutics?

Some factors that can affect the equity of Carisma Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Carisma Therapeutics so important for investors?

The equity of Carisma Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Carisma Therapeutics take to change the equity?

To change equity, Carisma Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Carisma Therapeutics pay?

Over the past 12 months, Carisma Therapeutics paid a dividend of 0.36 USD . This corresponds to a dividend yield of about 42.82 %. For the coming 12 months, Carisma Therapeutics is expected to pay a dividend of 0.36 USD.

What is the dividend yield of Carisma Therapeutics?

The current dividend yield of Carisma Therapeutics is 42.82 %.

When does Carisma Therapeutics pay dividends?

Carisma Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Carisma Therapeutics?

Carisma Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Carisma Therapeutics?

For the upcoming 12 months, dividends amounting to 0.36 USD are expected. This corresponds to a dividend yield of 42.82 %.

In which sector is Carisma Therapeutics located?

Carisma Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Carisma Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Carisma Therapeutics from 3/8/2023 amounting to 0.361 USD, you needed to have the stock in your portfolio before the ex-date on 3/8/2023.

When did Carisma Therapeutics pay the last dividend?

The last dividend was paid out on 3/8/2023.

What was the dividend of Carisma Therapeutics in the year 2023?

In the year 2023, Carisma Therapeutics distributed 0 USD as dividends.

In which currency does Carisma Therapeutics pay out the dividend?

The dividends of Carisma Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Carisma Therapeutics

Our stock analysis for Carisma Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Carisma Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.